News
Denali Therapeutics
DNLI · NASDAQ
$18.93+$0.89 (+4.93%)TodayMarket closed ·
Prev close $18.04
Latest news
- Press releaseGlobe Newswire
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
- Press releaseGlobe Newswire
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
- Press releaseGlobe Newswire
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
- Press releaseGlobe Newswire
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
- Press releaseGlobe Newswire
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
- NewsAnanya Gairola
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out'
- Press releaseGlobe Newswire
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
- NewsVandana Singh
Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why
- Press releaseGlobe Newswire
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
- Press releasePRNewswire
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
- NewsVandana Singh
FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease
- Press releaseGlobe Newswire
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
- News
FDA Approves Denali Therapeutics' Avlayah To Treat Hunter Syndrome
- Press releasePRNewswire
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
- Press releaseGlobe Newswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
- NewsVandana Singh
FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment
- Press releaseGlobe Newswire
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
- NewsAvi Kapoor
Cracker Barrel Posts Downbeat Q1 Results, Joins GameStop, AeroVironment And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why Braze Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- NewsVandana Singh
Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start
- NewsVandana Singh
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate
- News
'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA
- NewsVandana Singh
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback
- NewsVandana Singh
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
- NewsAvi Kapoor
This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday
- NewsAdam Eckert
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.